Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schiff branded sales grow behind Mega-D3 launch

This article was originally published in The Tan Sheet

Executive Summary

The Schiff Mega-D3 supplement, combining vitamin D3 and resveratrol, rolls out to retail as the Salt Lake City firm reports continued strong sales of branded products, particularly its MegaRed Krill Oil. However, softness in the joint care category hit Schiff Nutrition International's Move Free supplements and its private label business continued to struggle during the firm's fiscal 2011 first quarter, Schiff reported Sept. 14. Though net sales rose 5.9 percent to $51.4 million during the June-August period, net income dipped 16 percent to $3.7 million. Schiff CEO Bruce Wood said higher consumer advertising spending caused selling and marketing expenses to jump 40 percent to $9.3 million. The firm also announced a 70 cents-per-share special cash dividend to be paid Oct. 26 to shareholders as of Sept. 23

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts